clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Maurin M and Raoult D | In vitro susceptibilities of spotted fever group rickettsiae and Coxiella burnetti to clarithromycin. | 1993 | Antimicrob. Agents Chemother. | pmid:8109928 |
Parish LC | Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Clarithromycin Study Group. | 1993 | Int. J. Dermatol. | pmid:8340194 |
Akiyama H et al. | Interaction of Staphylococcus aureus cells and silk threads in vitro and in mouse skin. | 1993 | J. Dermatol. Sci. | pmid:8136322 |
Granier H et al. | [Mycobacterium chelonei arthritis in an immunosuppressed patient. Efficacy of the treatment with clarithromycin]. | 1993 | Ann Med Interne (Paris) | pmid:8141516 |
MacGowan AR et al. | Synergy testing of macrolide combinations using the chequerboard technique. | 1993 | J. Antimicrob. Chemother. | pmid:8144439 |
Ximenes E et al. | [Ciprofloxacin, clarithromycin, rifampin: in vitro bactericidal activity of double and triple drug combinations against strains of atypical mycobacteria]. | 1993 | Pathol. Biol. | pmid:8233629 |
Romand S et al. | In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii. | 1993 | Antimicrob. Agents Chemother. | pmid:8285620 |
Chien SM et al. | Treatment of community-acquired pneumonia. A multicenter, double-blind, randomized study comparing clarithromycin with erythromycin. Canada-Sweden Clarithromycin-Pneumonia Study Group. | 1993 | Chest | pmid:8449054 |
Watanabe Y et al. | Chemical modification of erythromycins. IX. Selective methylation at the C-6 hydroxyl group of erythromycin A oxime derivatives and preparation of clarithromycin. | 1993 | J. Antibiot. | pmid:8501007 |
Roig J et al. | Treatment of Legionnaires' disease. Current recommendations. | 1993 | Drugs | pmid:7691508 |
Klein JO | Clarithromycin: where do we go from here? | 1993 | Pediatr. Infect. Dis. J. | pmid:8295817 |
Hardy DJ | Extent and spectrum of the antimicrobial activity of clarithromycin. | 1993 | Pediatr. Infect. Dis. J. | pmid:8295818 |
Dubois J et al. | Efficacy of clarithromycin vs. amoxicillin/clavulanate in the treatment of acute maxillary sinusitis. | 1993 | Ear Nose Throat J | pmid:8313865 |
Nasu M | [Helicobacter pylori infections]. | 1993 | Nippon Naika Gakkai Zasshi | pmid:8315343 |
Lonks JR and Medeiros AA | High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, R.I. | 1993 | Antimicrob. Agents Chemother. | pmid:8239578 |
Guay DR et al. | Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. | 1993 | Drug Saf | pmid:8504017 |
Dever LL et al. | Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi. | 1993 | Antimicrob. Agents Chemother. | pmid:8215288 |
Fass RJ | Erythromycin, clarithromycin, and azithromycin: use of frequency distribution curves, scattergrams, and regression analyses to compare in vitro activities and describe cross-resistance. | 1993 | Antimicrob. Agents Chemother. | pmid:8257127 |
Dempsey CL et al. | Drug usage evaluation: clarithromycin as sequential therapy. | 1993 | Hosp Formul | pmid:10130382 |
Watanabe Y et al. | Chemical modification of erythromycins. XII. A facile synthesis of clarithromycin (6-O-methylerythromycin A) via 2'-silylethers of erythromycin A derivatives. | 1993 | J. Antibiot. | pmid:8360112 |